Rigel Pharma (RIGL) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $36.29 +1.57%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
MAYS, CRMT, REPL, More
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $20.4 million versus the consensus estimate of $21.9 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- AMC Entertainment prices $200M stock offering to redeem senior notes
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
